Does the media refer more to TNGX or ASND?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat Ascendis Pharma A/S's score of -0.02 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, EXEL or TNGX?

Exelixis has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.22 $782.57M $3.18 18.32 Tango Therapeutics $62.38M 63.32 -$101.59M -$0.85 N/A

Does the media favor EXEL or TNGX?

In the previous week, Exelixis had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 4 mentions for Exelixis and 3 mentions for Tango Therapeutics. Exelixis' average media sentiment score of 0.74 beat Tango Therapeutics' score of 0.59 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SMMT or TNGX more profitable?

Tango Therapeutics' return on equity of -25.75% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Tango Therapeutics N/A -25.75% -23.36%

Does the media favor SMMT or TNGX?

In the previous week, Summit Therapeutics had 17 more articles in the media than Tango Therapeutics. MarketBeat recorded 20 mentions for Summit Therapeutics and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat Summit Therapeutics' score of 0.42 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBIO or TNGX?

In the previous week, BridgeBio Pharma had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 4 mentions for BridgeBio Pharma and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat BridgeBio Pharma's score of 0.51 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HALO or TNGX?

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 6 mentions for Halozyme Therapeutics and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat Halozyme Therapeutics' score of 0.19 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tango Therapeutics (TNGX) Competitors

$23.24 -1.21 (-4.95%)

Closing price 04:00 PM Eastern

Extended Trading

$22.92 -0.31 (-1.36%)

As of 07:44 PM Eastern

Compare

TNGX vs. ASND, EXEL, SMMT, BBIO, and HALO

Should you buy Tango Therapeutics stock or one of its competitors? Tango Therapeutics's main competitors and comparable companies include Ascendis Pharma A/S (ASND), Exelixis (EXEL), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Tango Therapeutics (NASDAQ:TNGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Tango Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Tango Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	63.32	-$101.59M	-$0.85	N/A
Ascendis Pharma A/S	$814.57M	17.38	-$258M	$12.89	17.61

Tango Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Tango Therapeutics currently has a consensus target price of $43.46, indicating a potential upside of 85.52%. Ascendis Pharma A/S has a consensus target price of $310.75, indicating a potential upside of 36.94%. Given Tango Therapeutics' higher probable upside, research analysts clearly believe Tango Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

79.0% of Tango Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat Ascendis Pharma A/S's score of -0.02 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has a net margin of 70.99% compared to Tango Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Summary

Ascendis Pharma A/S beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Exelixis has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

In the previous week, Exelixis had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 4 mentions for Exelixis and 3 mentions for Tango Therapeutics. Exelixis' average media sentiment score of 0.74 beat Tango Therapeutics' score of 0.59 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a net margin of 35.33% compared to Tango Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Tango Therapeutics	N/A	-25.75%	-23.36%

85.3% of Exelixis shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Exelixis currently has a consensus price target of $50.29, indicating a potential downside of 13.68%. Tango Therapeutics has a consensus price target of $43.46, indicating a potential upside of 85.52%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Exelixis has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.22	$782.57M	$3.18	18.32
Tango Therapeutics	$62.38M	63.32	-$101.59M	-$0.85	N/A

Summary

Exelixis beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Tango Therapeutics has higher revenue and earnings than Summit Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Tango Therapeutics	$62.38M	63.32	-$101.59M	-$0.85	N/A

Tango Therapeutics' return on equity of -25.75% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Tango Therapeutics	N/A	-25.75%	-23.36%

Summit Therapeutics presently has a consensus target price of $28.61, suggesting a potential upside of 70.98%. Tango Therapeutics has a consensus target price of $43.46, suggesting a potential upside of 85.52%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summit Therapeutics has a beta of -1.51, meaning that its stock price is 251% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

In the previous week, Summit Therapeutics had 17 more articles in the media than Tango Therapeutics. MarketBeat recorded 20 mentions for Summit Therapeutics and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat Summit Therapeutics' score of 0.42 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tango Therapeutics beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Tango Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, BridgeBio Pharma had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 4 mentions for BridgeBio Pharma and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat BridgeBio Pharma's score of 0.51 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Tango Therapeutics	N/A	-25.75%	-23.36%

Tango Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Tango Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.24	-$724.93M	-$3.57	N/A
Tango Therapeutics	$62.38M	63.32	-$101.59M	-$0.85	N/A

BridgeBio Pharma currently has a consensus price target of $102.61, suggesting a potential upside of 52.26%. Tango Therapeutics has a consensus price target of $43.46, suggesting a potential upside of 85.52%. Given Tango Therapeutics' higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BridgeBio Pharma and Tango Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 6 mentions for Halozyme Therapeutics and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat Halozyme Therapeutics' score of 0.19 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics currently has a consensus target price of $91.20, indicating a potential downside of 16.22%. Tango Therapeutics has a consensus target price of $43.46, indicating a potential upside of 85.52%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Halozyme Therapeutics has a net margin of 24.86% compared to Tango Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Tango Therapeutics	N/A	-25.75%	-23.36%

Halozyme Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Halozyme Therapeutics has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.85	$316.89M	$3.35	32.49
Tango Therapeutics	$62.38M	63.32	-$101.59M	-$0.85	N/A

Summary

Halozyme Therapeutics beats Tango Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Tango Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNGX vs. The Competition

Export

Metric	Tango Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.12B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.76%
P/E Ratio	-27.34	7.65	214.49	21.54
Price / Sales	62.82	1,292.25	607.75	91.81
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	9.04	16.63	10.92	6.30
Net Income	-$101.59M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-6.74%	-3.05%	-2.11%	-1.67%
1 Month Performance	4.12%	-10.75%	-6.34%	-3.94%
1 Year Performance	202.21%	21.11%	8.81%	2.77%

Tango Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNGX Tango Therapeutics	2.3859 of 5 stars	$23.24 -4.9%	$43.46 +87.0%	+206.8%	$4.12B	$62.38M	N/A	137	Gap Up
ASND Ascendis Pharma A/S	4.7691 of 5 stars	$235.85 -0.7%	$310.75 +31.8%	+11.4%	$14.70B	$814.57M	18.29	1,189
EXEL Exelixis	3.1761 of 5 stars	$58.43 +2.1%	$50.29 -13.9%	+40.6%	$14.50B	$2.32B	18.41	1,077
SMMT Summit Therapeutics	2.8723 of 5 stars	$17.13 +1.4%	$25.91 +51.3%	-18.5%	$13.66B	N/A	N/A	265	Analyst Forecast
BBIO BridgeBio Pharma	3.0956 of 5 stars	$69.13 +3.8%	$102.61 +48.4%	+25.1%	$13.51B	$502.08M	N/A	839

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNGX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tango Therapeutics (TNGX) Competitors

TNGX vs. ASND, EXEL, SMMT, BBIO, and HALO

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Tango Therapeutics compare to Exelixis?

Summary

How does Tango Therapeutics compare to Summit Therapeutics?

Summary

How does Tango Therapeutics compare to BridgeBio Pharma?

Summary

How does Tango Therapeutics compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tango Therapeutics (TNGX) Competitors

TNGX vs. ASND, EXEL, SMMT, BBIO, and HALO

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Which has stronger earnings and valuation, TNGX or ASND?

Which has more risk & volatility, TNGX or ASND?

Do analysts recommend TNGX or ASND?

Do insiders and institutionals believe in TNGX or ASND?

Does the media refer more to TNGX or ASND?

Is TNGX or ASND more profitable?

Summary

How does Tango Therapeutics compare to Exelixis?

Which has more volatility & risk, EXEL or TNGX?

Does the media favor EXEL or TNGX?

Is EXEL or TNGX more profitable?

Do institutionals & insiders have more ownership in EXEL or TNGX?

Do analysts rate EXEL or TNGX?

Which has better valuation and earnings, EXEL or TNGX?

Summary

How does Tango Therapeutics compare to Summit Therapeutics?

Which has higher valuation and earnings, SMMT or TNGX?

Is SMMT or TNGX more profitable?

Do analysts recommend SMMT or TNGX?

Do institutionals and insiders hold more shares of SMMT or TNGX?

Which has more risk & volatility, SMMT or TNGX?

Does the media favor SMMT or TNGX?

Summary

How does Tango Therapeutics compare to BridgeBio Pharma?

Does the media prefer BBIO or TNGX?

Is BBIO or TNGX more profitable?

Which has preferable valuation & earnings, BBIO or TNGX?

Do analysts recommend BBIO or TNGX?

Which has more volatility and risk, BBIO or TNGX?

Do institutionals and insiders hold more shares of BBIO or TNGX?

Summary

How does Tango Therapeutics compare to Halozyme Therapeutics?

Does the media prefer HALO or TNGX?

Do analysts rate HALO or TNGX?

Is HALO or TNGX more profitable?

Which has more risk and volatility, HALO or TNGX?

Do insiders and institutionals have more ownership in HALO or TNGX?

Which has preferable valuation and earnings, HALO or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools